Misplaced Pages

Loi Huriet Sérusclat

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Loi Huriet Sérusclat" – news · newspapers · books · scholar · JSTOR (June 2015) (Learn how and when to remove this message)
This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. Please help improve this article by introducing more precise citations. (June 2015) (Learn how and when to remove this message)
(Learn how and when to remove this message)
Loi Huriet-Sérusclat
French Parliament
Long title
  • Loi n°88-1138 du 20 décembre 1988 relative à la protection des personnes se prêtant à des recherches biomédicales
Enacted20 December 1988
Introduced byClaude Huriet, Franck Sérusclat
Status: In force

The Loi du 20 décembre 1988 relative à la protection des personnes qui se prêtent à des recherches biomédicales, also known as the Loi Huriet or Loi Huriet-Sérusclat, is a French civil law to establish the regulation of those working in biomedical research, and to formalise the status quo of bioethics. It was proposed under the second government of Michel Rocard (Parti socialiste) six months after the 1988 French legislative election. It was the first French law that put clinical trials on a firm legal footing.

First statute

An appendix, IIb, to the French civil code on Public Health, established the Comité consultatif de protection des personnes dans la recherche biomédicale (CCPPRB), later succeeded by the Comités de protection des personnes (CPP). Its ambit, defined in Article 15, established in law the notion of a consentement éclairé (a "Clear consent", perhaps similar to the Clean hands doctrine in common law), and established penalties for breaking the law.

The common name Loi Sérusclat-Huriet, and abbreviated variations such as Loi Huriet and Loi Sérusclat, come from the names of the nominator and seconder in the French senate, Claude Huriet (Centrist) and Franck Sérusclat (Socialist).

Evolution

As cases came to court with the usual jurisprudence, public perception of the importance of bioethics and other European Union law, have supplemented the powers made under the original regulatory framework, such as French: Loi n°94-653 du 29 juillet 1994, relative au respect du corps humain ("Law of 29 July 1994, Respect of the human body"), which defined the legal notion of dignity, and Loi du 4 mars 2002 relative aux droits des malades et à la qualité du système de santé ("Law of 4 March 2002, Patient rights and the quality of health system").

Notes

  1. A French judge has far more investigative powers than those in Common law jurisdictions.

References

  • Defert, Daniel (1994). "La loi Huriet et le point de vue des malades". In Fagot-Largeault, Anne; Ghanassia, J.-P.; Lemaire, F. (eds.). Consentement éclairé et recherche clinique [Huriet Law and the point of view of those with illness] (in French). Paris: Flammarion. pp. 22–25.


Flag of FranceJustice icon

This article relating to the law of France is a stub. You can help Misplaced Pages by expanding it.

Categories:
Loi Huriet Sérusclat Add topic